vs

Side-by-side financial comparison of Invesco (IVZ) and PACS Group, Inc. (PACS). Click either name above to swap in a different company.

Invesco is the larger business by last-quarter revenue ($1.7B vs $1.4B, roughly 1.2× PACS Group, Inc.). PACS Group, Inc. runs the higher net margin — 4.4% vs -58.9%, a 63.3% gap on every dollar of revenue. On growth, PACS Group, Inc. posted the faster year-over-year revenue change (18.4% vs 6.2%). Over the past eight quarters, PACS Group, Inc.'s revenue compounded faster (20.5% CAGR vs 7.1%).

Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.

IVZ vs PACS — Head-to-Head

Bigger by revenue
IVZ
IVZ
1.2× larger
IVZ
$1.7B
$1.4B
PACS
Growing faster (revenue YoY)
PACS
PACS
+12.2% gap
PACS
18.4%
6.2%
IVZ
Higher net margin
PACS
PACS
63.3% more per $
PACS
4.4%
-58.9%
IVZ
Faster 2-yr revenue CAGR
PACS
PACS
Annualised
PACS
20.5%
7.1%
IVZ

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IVZ
IVZ
PACS
PACS
Revenue
$1.7B
$1.4B
Net Profit
$-995.9M
$59.7M
Gross Margin
Operating Margin
-86.2%
7.0%
Net Margin
-58.9%
4.4%
Revenue YoY
6.2%
18.4%
Net Profit YoY
-575.8%
3022.5%
EPS (diluted)
$-2.61
$0.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVZ
IVZ
PACS
PACS
Q4 25
$1.7B
$1.4B
Q3 25
$1.6B
$1.3B
Q2 25
$1.5B
$1.3B
Q1 25
$1.5B
$1.3B
Q4 24
$1.6B
$1.1B
Q3 24
$1.5B
$1.0B
Q2 24
$1.5B
$981.4M
Q1 24
$1.5B
$934.3M
Net Profit
IVZ
IVZ
PACS
PACS
Q4 25
$-995.9M
$59.7M
Q3 25
$356.4M
$52.4M
Q2 25
$197.4M
$51.0M
Q1 25
$171.1M
$28.5M
Q4 24
$209.3M
$1.9M
Q3 24
$55.0M
$15.6M
Q2 24
$132.2M
$-10.9M
Q1 24
$141.5M
$49.1M
Gross Margin
IVZ
IVZ
PACS
PACS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
17.1%
Q2 24
22.3%
Q1 24
21.2%
Operating Margin
IVZ
IVZ
PACS
PACS
Q4 25
-86.2%
7.0%
Q3 25
16.5%
6.4%
Q2 25
14.1%
6.2%
Q1 25
18.1%
3.8%
Q4 24
19.6%
1.7%
Q3 24
6.6%
2.2%
Q2 24
13.9%
0.1%
Q1 24
14.4%
8.6%
Net Margin
IVZ
IVZ
PACS
PACS
Q4 25
-58.9%
4.4%
Q3 25
21.7%
3.9%
Q2 25
13.0%
3.9%
Q1 25
11.2%
2.2%
Q4 24
13.1%
0.2%
Q3 24
3.6%
1.5%
Q2 24
8.9%
-1.1%
Q1 24
9.6%
5.3%
EPS (diluted)
IVZ
IVZ
PACS
PACS
Q4 25
$-2.61
$0.42
Q3 25
$0.66
$0.32
Q2 25
$-0.03
$0.31
Q1 25
$0.38
$0.17
Q4 24
$0.46
$-0.03
Q3 24
$0.12
$0.10
Q2 24
$0.29
$-0.07
Q1 24
$0.31
$0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVZ
IVZ
PACS
PACS
Cash + ST InvestmentsLiquidity on hand
$1.0B
$197.0M
Total DebtLower is stronger
$1.8B
$353.2M
Stockholders' EquityBook value
$12.2B
$946.8M
Total Assets
$27.1B
$5.6B
Debt / EquityLower = less leverage
0.15×
0.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVZ
IVZ
PACS
PACS
Q4 25
$1.0B
$197.0M
Q3 25
$973.1M
$355.7M
Q2 25
$922.7M
$294.2M
Q1 25
$821.7M
$287.5M
Q4 24
$986.5M
$157.7M
Q3 24
$1.0B
$49.5M
Q2 24
$878.5M
$73.4M
Q1 24
$895.7M
$81.2M
Total Debt
IVZ
IVZ
PACS
PACS
Q4 25
$1.8B
$353.2M
Q3 25
$1.6B
Q2 25
$1.9B
Q1 25
$964.8M
Q4 24
$890.6M
$411.9M
Q3 24
$890.3M
Q2 24
$890.1M
Q1 24
$1.3B
Stockholders' Equity
IVZ
IVZ
PACS
PACS
Q4 25
$12.2B
$946.8M
Q3 25
$14.0B
$871.3M
Q2 25
$13.9B
$806.8M
Q1 25
$14.7B
$750.2M
Q4 24
$14.6B
$709.6M
Q3 24
$14.8B
$660.0M
Q2 24
$14.6B
$572.1M
Q1 24
$14.6B
$128.0M
Total Assets
IVZ
IVZ
PACS
PACS
Q4 25
$27.1B
$5.6B
Q3 25
$28.4B
$5.6B
Q2 25
$28.5B
$5.5B
Q1 25
$28.1B
$5.5B
Q4 24
$27.0B
$5.2B
Q3 24
$27.5B
$4.5B
Q2 24
$27.2B
$3.9B
Q1 24
$28.1B
$3.9B
Debt / Equity
IVZ
IVZ
PACS
PACS
Q4 25
0.15×
0.37×
Q3 25
0.12×
Q2 25
0.14×
Q1 25
0.07×
Q4 24
0.06×
0.58×
Q3 24
0.06×
Q2 24
0.06×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVZ
IVZ
PACS
PACS
Operating Cash FlowLast quarter
$455.8M
$-3.4M
Free Cash FlowOCF − Capex
$432.2M
FCF MarginFCF / Revenue
25.5%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
-0.06×
TTM Free Cash FlowTrailing 4 quarters
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVZ
IVZ
PACS
PACS
Q4 25
$455.8M
$-3.4M
Q3 25
$606.2M
$204.8M
Q2 25
$547.9M
$52.6M
Q1 25
$-84.6M
$150.2M
Q4 24
$316.9M
$64.6M
Q3 24
$438.4M
$209.2M
Q2 24
$489.1M
$34.8M
Q1 24
$-54.4M
$58.8M
Free Cash Flow
IVZ
IVZ
PACS
PACS
Q4 25
$432.2M
Q3 25
$586.4M
Q2 25
$530.4M
Q1 25
$-108.0M
Q4 24
$309.9M
Q3 24
$410.0M
Q2 24
$462.4M
Q1 24
$-75.4M
FCF Margin
IVZ
IVZ
PACS
PACS
Q4 25
25.5%
Q3 25
35.7%
Q2 25
35.0%
Q1 25
-7.1%
Q4 24
19.5%
Q3 24
27.1%
Q2 24
31.2%
Q1 24
-5.1%
Capex Intensity
IVZ
IVZ
PACS
PACS
Q4 25
1.4%
Q3 25
1.2%
Q2 25
1.2%
Q1 25
1.5%
Q4 24
0.4%
Q3 24
1.9%
Q2 24
1.8%
Q1 24
1.4%
Cash Conversion
IVZ
IVZ
PACS
PACS
Q4 25
-0.06×
Q3 25
1.70×
3.91×
Q2 25
2.78×
1.03×
Q1 25
-0.49×
5.28×
Q4 24
1.51×
33.78×
Q3 24
7.97×
13.39×
Q2 24
3.70×
Q1 24
-0.38×
1.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IVZ
IVZ

Investment Advice$1.2B73%
Distribution And Shareholder Service$382.7M23%
Financial Service Other$51.0M3%
Investment Performance$28.9M2%

PACS
PACS

Segment breakdown not available.

Related Comparisons